In the BioHarmony Drug Report Database

"Preview" Icon

Exenatide

Bydureon, Bydureon Bcise, Bydureon Pen, Byetta (exenatide) is a protein pharmaceutical. Exenatide was first approved as Bydureon on 2005-04-28. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor. Bydureon’s patents are valid until 2030-10-04 (FDA).

 

Trade Name

 

Bydureon, Byetta
 

Common Name

 

exenatide
 

ChEMBL ID

 

CHEMBL414357
 

Indication

 

type 2 diabetes mellitus
 

Drug Class

 

Peptides

Image (chem structure or protein)

Exenatide structure rendering